Aim: We aimed to analyze the effects of adjunctive posterior sub-Tenon capsule triamcinolone acetonide injection in the treatment of intermediate uveitis macular edema in multiple sclerosis patients that could not be controlled by systemic corticosteroid medications and immunomodulators. Methods: The study included 30 eyes of 25 patients with multiple sclerosis who received a posterior sub-Tenon injection of 40 mg/mL triamcinolone acetonide. Parameters monitored for therapy efficiency were best-corrected visual acuity, intraocular pressure, central foveal thickness (CFT), and fluorescein angiography (FA) scores. Results: Mean best-corrected visual acuity was significantly improved at the control visit 0.15 ± 0.10 versus baseline 0.40 ± 0.20 logMAR (p < 0.05). Six eyes showed intraocular pressure spikes requiring topical antiglaucomatous treatment. Mean CFT and FA scores were significantly decreased versus baseline (CFT: 345 ± 50 μm; FA score: 3.4 ± 1.0) compared with the 12-week control visit (CFT: 219 ± 35 μm; FA score: 1.6 ± 1.1; p < 0.001). Conclusion: Posterior sub-Tenon injection of triamcinolone acetonide significantly improved visual acuity and decrease macular edema in patients with intermediate uveitis associated with multiple sclerosis.

Keywords:
Triamcinolone acetonide, Macular edema, Sub-Tenon capsule, Intermediate uveitis, Multiple sclerosis
1.
Goldhardt R, Rosen BS: Uveitic macular edema: treatment update. Curr Ophthalmol Rep 2016;4:30-37.
2.
Lardenoye CW, Van Koo IJ, Rothova A: Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113:1446-1449.
3.
Deuter CME, Kötter I, Günaydin I, et al: Interferon α-2A: a new treatment option for long lasting refractory cystoid macular edema in uveitis? Retina 2006;26:786-791.
4.
Bodaghi B, Gendron G, Wechsler B, et al: Efficacy of interferon α in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-359.
5.
Plskova J, Greiner K, Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61.
6.
Kempen JH, Altaweel MM: The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149:550-561.
7.
Preble JM, Foster SC: Uveitic macular edema: a stepladder treatment paradigm. Clin Invest Lond 2015;5:509-517.
8.
Coşkun E, Celemler P, Kimyon G, Öner V, Kisacik B, Erbagci I, Onat AM: Intravitreal dexamethasone implant for treatment of refractory Behçet posterior uveitis: one-year follow-up results. Ocul Immunol Inflamm 2015:23:437-444.
9.
Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
10.
Palmberg P: Risk factors for glaucoma progression: where does intraocular pressure fit in? Arch Ophthalmol 2001;119:897-898.
11.
Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H: Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol 2008;43:42-47.
12.
Gilles MC, Simson JM, Billson FA, Luo W, Penfold P, Chua W, et al: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
13.
Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW: Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-273.
14.
Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A: Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
15.
Negi AK, Browning AC, Vernon AS: Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: randomized controlled trial. J Cataract Refract Surg 2006;32:468-474.
16.
Byun YS, Park Y-H: Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009;25:159-162.
17.
Yannuzzi LA: A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol 1984;28:540-553.
18.
Tugal-Tutkun I, Herbort CP, Khairallah M; Angiography Scoring for Uveitis Working Group (ASUWOG): Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol 2010;30:539-552.
19.
Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, et al: The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophtalmol 1993;111:831-836.
20.
De Smith M, Okada A: Macular edema. Dev Ophthalmol 2010;47:136-147.
21.
Shen l, Chen Y, Sun S, Han Y, Cheng L: Transscleral permeation of subtenon triamcinolone in different vitreoretinal diseases. Ophthalmology 2015;122:649-651.
22.
Helm CJ, Holland GN: The effect of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.
23.
Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbot CP: Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237:289-295.
24.
Bleriot A, Couret C, Le Meuer G, Lebranchu P, Weber M: Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases (in French). J Fr Ophtalmol 2014;37:599-604.
25.
Liu X, Wang M, Zhao C, Gao F, Zhang M: The efficacy and safety of subconjunctival triamcinolone acetonide injections in treatment of uveitic macular edema. Zhonghua Yan Ke Za Zhi 2015;5:734-738.
26.
Lasave AF, Zeballos DG, EI-Haig WM, Diaz-Liopis M, Salo D, Arevalo JF: Short-term results of a single intravitreal bevacizumab (Avastin) injection versus a single intravitreal triamcinolone acetonide (Kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009;17:423-430.
27.
Bae JH, Lee CS, lee SC: Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-Tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011;31:111-118.
28.
Baneros-Rojas P, Berrozpe-Villabona C, Peraza-Nieves JE, Diaz-Valle D: Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Behçet' disease. Arc Soc Esp Oftalmol 2015;90:285-288.
29.
Kok H, Lau C, Maycock, N, McCluskey P, Lightman S: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2015;112:1916.e1-e7.
30.
De Smet MD, Julian K: The role of steroids in the management of uveitic macular edema. Eur J Ophthalmol 2011;21:S51-S55.
31.
Stanojevic-Paovic A, Jovanovic S, Zlatanovic G, Paovic J, Paovic P: Uveitisi diagnosticki i terapiski pristup. Medicinski fakultet Univerziteta u Kragujevcu, 2011, pp 165-195.
32.
Petrović N, Srećković S: Effect of intravitreal triamcinolone acetonide on improvement of visual acuity and resolution of diffuse diabetic macular oedema. Medicus 2007;8:5-10.
33.
Jovanović S, Vukosavljević M, Jovanović M, Stanojević-Paović A: Oftalmološke manifestacije hronične sarkoidoze. Ser J Exp Clin Res 2008;9:27-30.
34.
Zlatanović G, Jovanović S, Živković M, Zlatanović M, Srecković S, Radotić F: The efficacy of novel therapeutic modalities of isolated ocular vasculitis vs ocular vasculitis as a systemic disease. Med Glas (Zenica) 2012;9:66-73
35.
Ip M, Kahana A, Altaweel M: Treatment of central retinal vein occlusion with triamcinolone acetonide (an optical coherence tomography study). Semin Ophthalmol 2003;18:67-73.
36.
Gillies MC, Kuzniarz M, Craig J, et al: Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:593-599.
37.
Smithen LM, Ober MD, Maranan L, Spaide RF: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
38.
Inatani M, Iwao K, Kawaji T, Hirano Y, Ogura Y, Hirooka K, et al: Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol 2008;145:676-681.
39.
Pickrel A, Harris A, Ngo S, Amireskandari A, Stewart E, Siesky B: Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics 2012;4:230-242.
40.
Dal Canto AJ, Downs-Kelly E, Pery JD: Ptosis and orbital fat prolapse after posterior sub-Tenon's capsule triamcinolone injection. Ophthalmology 2006;112:1092-1097.
41.
Ferrante P, Ramsey A, Bunce C, Lightman S: Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 2004;32:563-568.
42.
Jouve L, Benrabah R, Heron E, Bodaghi B, Hoang PL, Touitou V: Multiple sclerosis-related uveitis: does MS treatment affect uveitis course? Ocul Immunol Inflamm 2016, pp 1-6, Epub ahead of print.
43.
Gordon LK, Goldstein DA: Gender and uveitis in patients with multiple sclerosis. 2014;2014:5652-5662.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.